Apixaban shows significantly lower bleeding risk than rivaroxaban in acute venous thromboembolism over 3 months in a ...

Study finds apixaban’s safety preferable over other anticoagulant medication following assessment of respective bleeding ...

The COBRRA randomized trial that compared direct oral anticoagulants (DOACs) for acute venous thromboembolism (VTE), and found apixaban to be associated with a significantly lower risk ...

The COBRRA trial directly tested apixaban and rivaroxaban, the oral anticoagulants most frequently used to treat acute venous thromboembolism. The risk of clinically relevant bleeding came out ...

In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial fibrillation, ...

The study, known as the Apixaban versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, ...

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...